Center for Reproductive Medicine, Shandong University, Jinan, Shandong, China.
Center for Reproductive Medicine, Shandong University, Jinan, Shandong, China.; Medical Integration and Practice Center, Shandong University, Jinan, Shandong, China..
Reprod Biomed Online. 2023 Nov;47(5):103307. doi: 10.1016/j.rbmo.2023.103307. Epub 2023 Jul 28.
Do infertile women with positive tuberculin skin test (TST) results have a higher risk of adverse pregnancy outcomes after IVF or intracytoplasmic sperm injection and embryo transfer (ICSI-ET) and does preventive anti-tuberculosis treatment applied to infertile women with positive TST results before IVF/ICSI-ET affect pregnancy and neonatal outcomes?
This was a retrospective cohort analysis of 6283 infertile women who underwent IVF/ICSI-ET treatment for the first time at the Reproductive Hospital affiliated to Shandong University from November 2016 to September 2022. None of the participants had prior tuberculosis or active tuberculosis. According to their TST results, 5947 patients who had never received preventive anti-tuberculosis treatment were divided into a TST-positive group (1704 cases) and a TST-negative group (4243 cases). A total of 504 patients with TST (+++) results (using the 20 mm sclerosis threshold) were divided into a treated TST (+++) group (336 cases) and an untreated TST (+++) group (168 cases) according to whether they received preventive anti-tuberculosis treatment before IVF/ICSI-ET. The outcome measures were pregnancy outcomes and neonatal outcomes.
There were no significant differences in pregnancy or neonatal outcomes between the TST-positive group and the TST-negative group (P > 0.05). In the TST (+++) group, there were no significant differences in pregnancy or neonatal outcomes between the treated TST (+++) group and the untreated TST (+++) group (P > 0.05).
For infertile women undergoing IVF/ICSI-ET without prior tuberculosis or active tuberculosis, positive TST results and preventive anti-tuberculosis treatments prior to IVF/ICSI-ET do not affect pregnancy or neonatal outcomes.
结核菌素皮肤试验(TST)阳性的不孕妇女在接受体外受精或卵胞浆内单精子注射和胚胎移植(ICSI-ET)后不良妊娠结局的风险是否更高,以及在接受 IVF/ICSI-ET 之前对 TST 阳性的不孕妇女进行预防性抗结核治疗是否会影响妊娠和新生儿结局?
这是一项对 2016 年 11 月至 2022 年 9 月期间在山东大学附属生殖医院首次接受体外受精/卵胞浆内单精子注射治疗的 6283 名不孕妇女进行的回顾性队列分析。所有参与者均无既往结核病或活动性结核病。根据 TST 结果,将从未接受过预防性抗结核治疗的 5947 名患者分为 TST 阳性组(1704 例)和 TST 阴性组(4243 例)。TST(+++)结果(采用 20mm 硬结阈值)的 504 例患者根据是否在接受 IVF/ICSI-ET 前接受预防性抗结核治疗分为治疗 TST(+++)组(336 例)和未治疗 TST(+++)组(168 例)。结局指标为妊娠结局和新生儿结局。
TST 阳性组与 TST 阴性组之间的妊娠或新生儿结局无显著差异(P>0.05)。在 TST(+++)组中,治疗 TST(+++)组与未治疗 TST(+++)组之间的妊娠或新生儿结局无显著差异(P>0.05)。
对于无既往结核病或活动性结核病的接受 IVF/ICSI-ET 的不孕妇女,TST 阳性结果和 IVF/ICSI-ET 前的预防性抗结核治疗并不影响妊娠或新生儿结局。